The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differences of TILs, hormone receptor, and HER2 status between primary and metastatic tumors.
 
Makiko Ono
No Relationships to Disclose
 
Tomo Osako
No Relationships to Disclose
 
Shinichiro Taira
No Relationships to Disclose
 
Tomoko Shibayama
No Relationships to Disclose
 
Kokoro Kobayashi
No Relationships to Disclose
 
Takayuki Kobayashi
No Relationships to Disclose
 
Naoya Gomi
No Relationships to Disclose
 
Takuji Iwase
No Relationships to Disclose
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Pfizer
Research Funding - Eisai
 
Yoshinori Ito
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); EPS Associates Co., Ltd. (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Parexel (Inst)
 
Shinji Ohno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Novartis Pharmaceuticals UK Ltd.; Pfizer; Sanofi/Aventis; Taiho Pharmaceutical
 
Futoshi Akiyama
No Relationships to Disclose
 
Shunji Takahashi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Novartis; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis